Mineralys Therapeutics, Inc. - Common Stock

Share · US6031701013 · MLYS (XNAS)

Overview

AI-Powered Analysis

Fundamental Analysis

Find out what the numbers really say — before the market does

Analyze now

News Sentiment

Are today's headlines a buy signal or a red flag?

Analyze now

Buy / Hold / Sell

Should you Buy, Hold, or Sell? Get the AI verdict now.

Analyze now

Risk Assessment

Uncover hidden risks before they hit your portfolio.

Analyze now

Fair Value

Is this stock cheap, fairly priced, or overvalued?

Analyze now

Latest AI Analyses of Mineralys Therapeutics, Inc. - Common Stock

Analyst Grade Summary

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

No Price

28.04.2026 20:00

Current Prices from Mineralys Therapeutics, Inc. - Common Stock

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
NASDAQ	MLYS	USD	28.04.2026 20:00	25,89 USD	-1,10 USD -4,08 %
IEX	MLYS	USD	28.04.2026 19:59	25,89 USD	-1,10 USD -4,08 %

Share Float & Liquidity

Free Float 69,64 %

Shares Float 46,17 M

Shares Outstanding 66,3 M

Company Profile for Mineralys Therapeutics, Inc. - Common Stock Share

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.